γ-Secretase Modulator BPN15606 Reduced Aβ42 and Aβ40 and Countered Alzheimer-Related Pathologies in a Mouse Model of Down Syndrome

Xu-Qiao Chen; Ann Becker; Ricardo Albay; Phuong D Nguyen; Dmitry Karachentsev; Amanda J Roberts; Kevin D Rynearson; Rudolph E Tanzi; William C Mobley

doi:10.1002/ana.26958

γ-Secretase Modulator BPN15606 Reduced Aβ42 and Aβ40 and Countered Alzheimer-Related Pathologies in a Mouse Model of Down Syndrome

Ann Neurol. 2024 May 15. doi: 10.1002/ana.26958. Online ahead of print.

Authors

Xu-Qiao Chen¹, Ann Becker¹, Ricardo Albay¹, Phuong D Nguyen¹, Dmitry Karachentsev¹, Amanda J Roberts², Kevin D Rynearson¹, Rudolph E Tanzi³, William C Mobley¹

Affiliations

¹ Department of Neurosciences, University of California San Diego, La Jolla, CA, USA.
² Animal Models Core Facility, The Scripps Research Institute, La Jolla, CA, USA.
³ Genetics and Aging Research Unit, McCance Center for Brain Health, Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.

PMID: 38747498
DOI: 10.1002/ana.26958

Abstract

Objectives: Due to increased gene dose for the amyloid precursor protein (APP), elderly adults with Down syndrome (DS) are at a markedly increased risk of Alzheimer's disease (AD), known as DS-AD. How the increased APP gene dose acts and which APP products are responsible for DS-AD is not well understood, thus limiting strategies to target pathogenesis. As one approach to address this question, we used a novel class of γ-secretase modulators that promote γ-site cleavages by the γ-secretase complex, resulting in lower levels of the Aβ42 and Aβ40 peptides.

Methods: Ts65Dn mice, which serve as a model of DS, were treated via oral gavage with 10 mg/kg/weekday of BPN15606 (a potent and novel pyridazine-containing γ-secretase modulators). Treatment started at 3 months-of-age and lasted for 4 months.

Results: Demonstrating successful target engagement, treatment with BPN15606 significantly decreased levels of Aβ40 and Aβ42 in the cortex and hippocampus; it had no effect on full-length APP or its C-terminal fragments in either 2 N or Ts65Dn mice. Importantly, the levels of total amyloid-β were not impacted, pointing to BPN15606-mediated enhancement of processivity of γ-secretase. Additionally, BPN15606 rescued hyperactivation of Rab5, a protein responsible for regulating endosome function, and normalized neurotrophin signaling deficits. BPN15606 treatment also normalized the levels of synaptic proteins and tau phosphorylation, while reducing astrocytosis and microgliosis, and countering cognitive deficits.

Interpretation: Our findings point to the involvement of increased levels of Aβ42 and/or Aβ40 in contributing to several molecular and cognitive traits associated with DS-AD. They speak to increased dosage of the APP gene acting through heightened levels of Aβ42 and/or Aβ40 as supporting pathogenesis. These findings further the interest in the potential use of γ-secretase modulators for treating and possibly preventing AD in individuals with DS. ANN NEUROL 2024.

Abstract

Grants and funding